Zimmer Biomet Launches PrimaGen Advanced Allograft
Zimmer Biomet launched PrimaGen Advanced™ Allograft, an autograft substitute comprising cancellous bone + demineralized cortical bone fibers with verified osteoinductivity. Dec 14, 2016
FDA Approves Vericel’s MACI for Treatment of Adult Symptomatic Knee Cartilage Defects
FDA approved Vericel’s MACI® for the repair of adult symptomatic single or multiple full-thickness cartilage defects of the knee. Dec 14, 2016
New DUROLANE Agreement
Bioventus entered into an agreement with Galderma to bring DUROLANE knee osteoarthritis treatment to the U.S. Dec 14, 2016
12-month Clinical and Radiographic Results with SImmetry Sacroiliac Joint Fusion
Results from a study of Zyga Technology’s SImmetry® Sacroiliac Joint Fusion procedure indicate that, at 12 months, fusion was reported in 88% of patients and back pain decreased by 46%. Dec 14, 2016
Jury Finds in Favor of Arthrex vs. Smith & Nephew
Arthrex was granted US $17MM+ in damages following a jury finding of willful infringement by Smith & Nephew/ArthroCare on two Arthrex patents relative to knotless and cross-support technology. Dec 13, 2016
GE Concludes Offers for Concept Laser, Arcam
GE completed its agreements to acquire stakes in Arcam and Concept Laser. Dec 12, 2016
Amplitude Surgical Acquires 50% Stake in SOFAB Orthopedie
Amplitude Surgical acquired a 50% stake in industrial subcontractor SOFAB Orthopedie. Dec 12, 2016
10th Anniversary of OMNIlife APEX Knee
OMNIlife science marked the 10th anniversary of the launch of the APEX Knee™, which has been used in >75,000 total knee procedures since 2006. Dec 12, 2016
OrthoMend Acquires License to Absorbable Bone Fixation, Repair Technologies
OrthoMend Research acquired from Temple University researchers an exclusive license to develop novel absorbable bone fixation and regenerative repair technologies for commercial use. Dec 09, 2016
Three-Month Interim Safety Data from Phase I Clinical Trial of AlloJoin
Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine’s AlloJoin™ off-the-shelf allogeneic stem cell therapy in the treatment of knee osteoarthritis demonstrated a safety and tolerability profile of AlloJoin in the three doses tested, with adverse events similar to that of earlier autologous trials. The trial is slated for completion in 3Q17. Dec 09, 2016
